Vaxxas Awarded US$3.67 million (AU$5.4 million) from global charitable foundation, Wellcome, for Human Clinical Study of Typhoid Vaccination using Needle-Free Vaccine Patch

CAMBRIDGE, Mass. & BRISBANE, Queensland, Australia--(BUSINESS WIRE)--Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced that the global

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Brisbane ,Queensland ,Australia ,United States ,Australian ,Gyun Kim ,Kathryn Morris ,Jeannies Pak ,Changhyun Jin ,Davidl Hoey ,Pierre Balard ,Amy Miller ,Jaeyong Ahn ,World Health Organization ,International Vaccine Institute ,Oneventures Innovation Fund ,University Of Queensland ,Wellcome ,Wellcome Media Office ,Development Authority ,Communications Team ,Senior Research ,Australian Government Innovation Investment Fund ,Yates Network ,Melinda Gates Foundation ,United States Biomedical Advanced Research ,Salmonella Typhi ,Senior Research Manager ,Melinda Gates ,Drug Safety ,Brandon Capital Partners ,Healthcare Ventures ,Brandon Biocatalyst ,Australian Government ,Innovation Investment Fund ,Media Office ,Press Release , ,